News + Resources

Innovations Advanced by M&A: A Novel Treatment for Atopic Dermatitis

Innovations Advanced by M&A: A Novel Treatment for Atopic Dermatitis

For many early-stage life sciences companies, mergers and acquisitions (M&A) represent a critical path. M&A helps companies unlock the complementary resources and expertise that help advance a new therapy from the lab to patients at scale. For example, Dermira’s acquisition by Eli Lilly & Co. helped bring Ebglyss, a novel monoclonal antibody treatment, to patients living with moderate-to-severe atopic dermatitis (AD).

read more
The Future of Antitrust: Key Takeaways from the 2024 National Lawyers Convention

The Future of Antitrust: Key Takeaways from the 2024 National Lawyers Convention

During a recent panel discussion at the 2024 National Lawyers Convention, leading antitrust experts underscored the impact of recent policy shifts from the Federal Trade Commission (FTC) and Department of Justice (DOJ). In America’s life sciences ecosystem, the FTC and DOJ’s policies have risked stifling pro-competitive mergers and acquisitions (M&A), which help companies of all sizes bring new treatments to patients.

read more